Cereno Scientific invites shareholders and investors to a digital investor meeting and Q&A
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech company pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, invites shareholders, investors and other interested parties to a digital investor meeting on Friday, November 27, 2026. The meeting follows the announcement of the intended rights issue and will focus on the Company's financing and priorities going forward.
On November 12, 2026, Cereno Scientific announced its intention to carry out a rights issue of units totaling approximately SEK 400 million. The announcement has raised questions and concerns among shareholders, which the Company wishes to address and clarify.
In response to requests for further information and dialogue, Cereno Scientific is hosting a digital investor meeting dedicated primarily to answering questions from shareholders and investors. Following a brief introduction by the Company, an external moderator will lead the Q&A session.
Shareholders and other interested parties are encouraged to submit questions in advance. Questions will be grouped by topic and addressed during the meeting, with a focus on the planned rights issue, the Company's financial position and its plans going forward.
Sten R. Sörensen, CEO of Cereno Scientific, comments:"We want to give our shareholders a clearer understanding of the planned financing, how the proceeds will be used and our priorities going forward. The meeting provides an opportunity to explain the rationale behind the proposal in greater detail and answer shareholders' questions. We value our shareholders' engagement and welcome questions both ahead of and during the meeting."
Meeting details
Date: Friday, November 27, 2026
Time: 12:00 CET
Meeting link: https://www.youtube.com/live/TrJ6mJAm1Qw
Submit questions to: fraga@investorstudios.se
Deadline for submitting questions: November 25, 2026
The meeting is open to shareholders, investors and other interested parties. A recording of the meeting, together with a summary of the questions and answers, will be made available on the Company's website, www.cerenoscientific.com, following the meeting.